Hsbc Holdings PLC Purchases Shares of 216,949 AnaptysBio, Inc. $ANAB

Hsbc Holdings PLC purchased a new position in shares of AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 216,949 shares of the biotechnology company’s stock, valued at approximately $14,928,000. Hsbc Holdings PLC owned about 0.73% of AnaptysBio as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ANAB. AQR Capital Management LLC raised its holdings in shares of AnaptysBio by 153.3% during the 1st quarter. AQR Capital Management LLC now owns 30,011 shares of the biotechnology company’s stock valued at $558,000 after buying an additional 18,165 shares in the last quarter. Creative Planning grew its position in AnaptysBio by 26.9% during the second quarter. Creative Planning now owns 16,854 shares of the biotechnology company’s stock valued at $374,000 after acquiring an additional 3,571 shares during the last quarter. JPMorgan Chase & Co. grew its position in AnaptysBio by 1,631.6% during the second quarter. JPMorgan Chase & Co. now owns 247,625 shares of the biotechnology company’s stock valued at $5,497,000 after acquiring an additional 233,325 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in shares of AnaptysBio during the second quarter worth approximately $528,000. Finally, Arrowstreet Capital Limited Partnership purchased a new position in shares of AnaptysBio during the second quarter worth approximately $3,348,000.

Get AnaptysBio alerts:

AnaptysBio Price Performance

ANAB opened at $57.29 on Friday. AnaptysBio, Inc. has a one year low of $11.40 and a one year high of $72.36. The business has a 50 day simple moving average of $58.57 and a two-hundred day simple moving average of $59.07. The firm has a market capitalization of $1.70 billion, a price-to-earnings ratio of -53.05 and a beta of 0.72.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ANAB shares. Leerink Partners set a $90.00 price objective on shares of AnaptysBio in a research note on Friday, May 15th. HC Wainwright reiterated a “buy” rating and issued a $95.00 target price on shares of AnaptysBio in a research report on Monday. Barclays boosted their price target on shares of AnaptysBio from $63.00 to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th. Piper Sandler cut their price target on shares of AnaptysBio from $95.00 to $93.00 and set an “overweight” rating for the company in a research report on Monday, May 4th. Finally, Zacks Research cut AnaptysBio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Ten analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, AnaptysBio presently has a consensus rating of “Moderate Buy” and a consensus target price of $80.00.

Get Our Latest Research Report on AnaptysBio

AnaptysBio Company Profile

(Free Report)

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.

Featured Articles

• Five stocks we like better than AnaptysBio
• Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
• SEC Probe Puts Wall Street Leverage Risk Back in Focus
• A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
• Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?

Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio, Inc. (NASDAQ:ANAB – Free Report).

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.